R. Scott

发表

Cardiovascular drug development: is it dead or just hibernating?

D. DeMets, P. Libby, R. Califf, 2015, Journal of the American College of Cardiology.

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study

R. Rosenson, E. Stroes, L. Cho, 2014, Cardiovascular Drugs and Therapy.

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Jennifer G. Robinson, J. D. Jordan, G. Molenberghs, 2016, Journal of the American Heart Association.

Effect of evolocumab on cholesterol synthesis and absorption[S]

S. Wasserman, R. Scott, Ransi M. Somaratne, 2016, Journal of Lipid Research.

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

F. Raal, E. Stein, S. Wasserman, 2012, Circulation.

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

R. Giugliano, M. Sabatine, M. Eriksson, 2014, Journal of the American College of Cardiology.

HIV and Hepatitis C – Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 ( PCSK 9 ) : An Apparent “ PCSK 9 – Lipid Paradox ”

P. Ganz, C. Grunfeld, P. Kohli, 2016 .

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

P. Ganz, C. Grunfeld, P. Kohli, 2016, Journal of the American Heart Association.

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial

P. Thompson, C. Ballantyne, S. Nissen, 2016, Clinical cardiology.

Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial ☆ ☆☆

T. Callister, P. Raggi, G. Bachmann, 2001 .

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

F. Raal, D. Blom, E. Stein, 2015, The Lancet.

AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody in

R. Giugliano, M. Sabatine, N. Desai, 2014, Journal of the American College of Cardiology.

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

G. Watts, S. Wasserman, R. Scott, 2018, Arteriosclerosis, thrombosis, and vascular biology.

Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067.

J. Kane, R. Scott, M. Davidson, 2007, Journal of clinical lipidology.

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

F. Raal, E. Stein, N. Honarpour, 2013, Circulation.

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[S]

R. Giugliano, M. Sabatine, N. Seidah, 2016, Journal of Lipid Research.

The In Vitro Effects of a Novel Vascular Protectant, AGI-1067, on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease

V. Serebruany, R. Scott, A. Malinin, 2006, Journal of cardiovascular pharmacology and therapeutics.

Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance

D. Blom, S. Wasserman, R. Scott, 2015 .

Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.

D. Blom, S. Wasserman, R. Scott, 2015, Circulation research.

AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAPLACE-TIMI 57 Trial

R. Giugliano, M. Sabatine, N. Desai, 2013 .

Abstract 17016: Trial Assessing Long-Term Use of PCSK9 Inhibition in Patients with Genetic LDL Disorders (TAUSSIG): Efficacy and Safety in Patients with Homozygous Familial Hypercholesterolemia Receiving Lipid Apheresis

F. Raal, E. Stein, E. Bruckert, 2014 .

Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial

F. Raal, D. Blom, E. Stein, 2014 .

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab

R. Giugliano, M. Sabatine, N. Desai, 2017, JAMA cardiology.

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolem

F. Raal, E. Stein, S. Wasserman, 2012 .

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

G. Watts, R. Rosenson, E. Bruckert, 2014, Journal of the American College of Cardiology.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

C. Ballantyne, E. Stein, R. Češka, 2014, The New England journal of medicine.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

R. Giugliano, M. Sabatine, N. Desai, 2012, The Lancet.

Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

R. Giugliano, M. Sabatine, N. Desai, 2012, Clinical cardiology.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

G. Watts, S. Marcovina, S. Wasserman, 2018, European heart journal.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Jennifer G. Robinson, R. Giugliano, M. Sabatine, 2015, The New England journal of medicine.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Lesley Burgess, Russell Scott, Rob Scott, 2015, The Lancet.

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

G. Watts, S. Wasserman, R. Scott, 2017, Circulation.

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

H. Bays, S. Wasserman, R. Scott, 2014, Journal of the American College of Cardiology.

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.

C. Ballantyne, S. Nissen, R. Rosenson, 2016, JAMA.

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

A. Keech, R. Giugliano, M. Sabatine, 2016, American heart journal.

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

S. Solomon, K. Mahaffey, T. Povsic, 2017, Cardiovascular Drugs and Therapy.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.

Answering the unanswered questions: ongoing trials of statins and antihypertensives in type 2 diabetes

R. Scott, 2002, Acta Diabetologica.

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

W. Koenig, C. Ballantyne, J. Kastelein, 2016, JAMA.

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).

W. Koenig, C. Ballantyne, J. Kastelein, 2016, American heart journal.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

S. Wasserman, R. Scott, Thomas Liu, 2012, The Lancet.

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, JAMA.

Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.

D. Karalis, R. Scott, A. Ross, 2002, The American journal of cardiology.

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy

R. Rosenson, E. Stroes, L. Cho, 2014, Clinical cardiology.

Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.

S. Hazen, J. Tardif, M. Brennan, 2008, Atherosclerosis.

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, Clinical cardiology.

Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy

V. Serebruany, C. Kunsch, R. Scott, 2009, Journal of Thrombosis and Thrombolysis.

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

Jean-Claude Tardif, Marc A Pfeffer, Robert Small, 2008, The Lancet.

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

V. Gebski, E. Stein, A. Olsson, 2012, JAMA.

Abstract 16196: Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9

R. Giugliano, M. Sabatine, N. Desai, 2014 .

Abstract 16865: Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)

R. Giugliano, E. Stroes, S. Wasserman, 2014 .

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.

T. Callister, P. Raggi, G. Bachmann, 2001, American heart journal.

Abstract 15743: Long-Term Reduction in Lipoprotein (a) With the PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of 3278 Patients in Phase 2, 3, and Open Label Extension Studies

R. Giugliano, M. Sabatine, F. Raal, 2014 .